Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL
Open Access
- 12 June 2014
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 123 (24), 3727-3732
- https://doi.org/10.1182/blood-2013-11-538116
Abstract
Key Points MRD eradication is a desirable end point in chronic lymphocytic leukemia. Early MRD eradication may prompt treatment discontinuation.This publication has 23 references indexed in Scilit:
- Should Minimal Residual Disease Monitoring in Acute Lymphoblastic Leukemia be Standard of Care?Current Hematologic Malignancy Reports, 2012
- Assessment of minimal residual disease in acute myeloid leukemiaCurrent Opinion in Oncology, 2010
- Is MRD eradication a desirable goal in CLL?Best Practice & Research Clinical Haematology, 2010
- Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysisLeukemia, 2009
- Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensBlood, 2009
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2007
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005